| Patients, n(%) |
---|---|
Bacterial culture results | 36(43.4%) |
 Sputum bacteria culture positive | 22(26.5%) |
 Blood bacteria culture positive | 9(10.8%) |
 Urine bacteria culture positive | 5(6.2%) |
 Fecal bacteria culture positive | 0 |
Complications | |
 Acute respiratory failure | 71(85.5%) |
 Acute myocardial infarction | 6(7.2%) |
 Heart failure | 37(44.6%) |
 Acute liver injury | 9(10.8%) |
 Acute kidney injury | 22(26.5%) |
 Gastrointestinal bleeding | 16(19.2%) |
 Sepsis | 69(83.1%) |
 Shock | 33(39.8%) |
Treatments | |
 Antiviral therapy | 83(100%) |
  Monotherapy | |
   Abidole | 6(7.2%) |
  Combination therapyAbidole | |
   Abidole/ Oseltamivir | 57(68.7%) |
   Abidole/ Ribavirin | 16(19.3%) |
   Abidole/ Lopinavir and Ritonavir | 3(3.6%) |
   Abidole/ Oseltamivir/ Lopinavir and Ritonavir | 1(1.2%%) |
 Antifungal therapy | 2(2.4%%) |
 Antibiotic therapy | 81(97.6%) |
  Penicillins | 24(28.9%) |
  Cephalosporins | 52(62.7%) |
  Quinolone | 35(42.2%) |
  Vancomycin | 11(13.3%) |
 Glucocorticoid therapy | 54(65.1%) |
 Intravenous immunoglobulin therapy | 39(47.0%) |
 CRRT | 6(7.3%) |
 Invasive mechanical ventilation | 20(24.1%) |
 Non-invasive mechanical ventilation | 51(61.4%) |
 High flow nasal cannula | 12(14.5%) |
 ECMO | 1(1.2%) |